Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study.
Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study.
复制标题
DOI：
10.1038/s41398-018-0183-x
复制
发表时间：
2018-07-10
影响因子：
6.8
通讯作者：
Xie P
中科院分区：
文献类型：
--
作者：
Pan JX;Xia JJ;Deng FL;Liang WW;Wu J;Yin BM;Dong MX;Chen JJ;Ye F;Wang HY;Zheng P;Xie P
重度抑郁症（MDD）是一种使人衰弱的精神疾病。然而，目前还没有针对这种疾病的客观的基于实验室的诊断测试。虽然，在多个神经递质系统的扰动已牵连在MDD，生化变化的障碍仍然不清楚，并在MDD的神经递质的全面的全球性评价尚未进行。在这里，使用GC-MS结合基于LC-MS/MS的靶向代谢组学方法，我们同时定量了50名首次发作的抗抑郁药初治MDD受试者和50名健康对照者中涉及GABA能、儿茶酚胺能和多巴胺能神经递质系统的19种血浆代谢物的水平，以确定MDD的潜在代谢物生物标志物（训练集）。此外，进一步使用包括49名MDD患者、30名双相情感障碍（BD）患者和40名健康对照（测试集）的独立样本队列来验证这些候选生物标志物的诊断普遍性和特异性。在检测的19种血浆神经递质代谢物中，9种在MDD受试者中发生了显著变化。这些代谢产物主要参与GABA能、儿茶酚胺能和多巴胺能系统。γ-氨基丁酸能和儿茶酚胺能的诊断价值高于肾上腺素能。一组四种候选血浆代谢物生物标志物（GABA、多巴胺、酪胺、犬尿氨酸）可以区分MDD受试者和健康对照者，在训练集和测试集中AUC分别为0.968和0.953。此外，该组以高准确度区分MDD受试者和BD受试者。这项研究是第一个全面评估MDD血浆中多种神经递质的研究。改变的血浆神经递质代谢物谱对MDD具有潜在的鉴别诊断价值。
Major depressive disorder (MDD) is a debilitating psychiatric illness. However, there is currently no objective laboratory-based diagnostic tests for this disorder. Although, perturbations in multiple neurotransmitter systems have been implicated in MDD, the biochemical changes underlying the disorder remain unclear, and a comprehensive global evaluation of neurotransmitters in MDD has not yet been performed. Here, using a GC-MS coupled with LC-MS/MS-based targeted metabolomics approach, we simultaneously quantified the levels of 19 plasma metabolites involved in GABAergic, catecholaminergic, and serotonergic neurotransmitter systems in 50 first-episode, antidepressant drug-naïve MDD subjects and 50 healthy controls to identify potential metabolite biomarkers for MDD (training set). Moreover, an independent sample cohort comprising 49 MDD patients, 30 bipolar disorder (BD) patients and 40 healthy controls (testing set) was further used to validate diagnostic generalizability and specificity of these candidate biomarkers. Among the 19 plasma neurotransmitter metabolites examined, nine were significantly changed in MDD subjects. These metabolites were mainly involved in GABAergic, catecholaminergic and serotonergic systems. The GABAergic and catecholaminergic had better diagnostic value than serotonergic pathway. A panel of four candidate plasma metabolite biomarkers (GABA, dopamine, tyramine, kynurenine) could distinguish MDD subjects from health controls with an AUC of 0.968 and 0.953 in the training and testing set, respectively. Furthermore, this panel distinguished MDD subjects from BD subjects with high accuracy. This study is the first to globally evaluate multiple neurotransmitters in MDD plasma. The altered plasma neurotransmitter metabolite profile has potential differential diagnostic value for MDD.
登录
查看更多内容
影响因子：
3.7
作者：
Chen JJ;Huang H;Zhao LB;Zhou DZ;Yang YT;Zheng P;Yang DY;He P;Zhou JJ;Fang L;Xie P
通讯作者：
Xie P
初次用药精神病中的网络级脱节：分离跨诊断和诊断特异性改变
DOI：
10.1038/npp.2016.247
发表时间：
2017-03
期刊：
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
影响因子：
--
作者：
Gong Q;Hu X;Pettersson-Yeo W;Xu X;Lui S;Crossley N;Wu M;Zhu H;Mechelli A
通讯作者：
Mechelli A
影响因子：
11
作者：
Milak MS;Proper CJ;Mulhern ST;Parter AL;Kegeles LS;Ogden RT;Mao X;Rodriguez CI;Oquendo MA;Suckow RF;Cooper TB;Keilp JG;Shungu DC;Mann JJ
通讯作者：
Mann JJ
影响因子：
168.9
作者：
Cipriani, Andrea;Zhou, Xinyu;Xie, Peng
通讯作者：
Xie, Peng
影响因子：
6.6
作者：
Gadad BS;Jha MK;Czysz A;Furman JL;Mayes TL;Emslie MP;Trivedi MH
通讯作者：
Trivedi MH